Caracas, Venezuela, 22 June 2021 — The Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), a product of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), has received registration approval from the Venezuelan authority Servicio Autónomo de Contraloría Sanitaria (SACS).
Firehawk® is a drug-eluting stent (DES) featuring strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. It allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug whilst significantly reducing the drug loading.
Previously, products developed by Microport®, such as Firebird 2®, Foxtrot® NC and Firefighter™, have been launched in Venezuela. The registration approval of Firehawk® further enriches Microport®’s coronary product portfolio in Venezuela and expands Microport®’s global footprint of coronary products. In the future, Microport® will continue to strengthen its efforts in local markets and provide high-quality total medical solutions to patients and doctors worldwide.
About Shangai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®) is a subsidiary of MicroPort Scientific Corporation (00853.HK). MicroPort® has grown over the years to become one of the leading manufacturers of medical devices. Its products cover a wide range of medical fields, including cardio rhythm management, orthopedic devices, vascular intervention, surgical management, and more. As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA.